Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers

NCT05582031 is registered in ClinicalTrials.gov with Translational Research in Oncology as lead sponsor.

NCT NCT05582031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers
Lead sponsor
Translational Research in Oncology
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2023
Completion date
April 30, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma, castrate resistant prostate cancer, colorectal neoplasms, gastroenteropancreatic neuroendocrine neoplasm, malignant pleural mesothelioma, neuroendocrine carcinoma of prostate, small cell lung carcinoma, soft tissue sarcoma